

Interventions for quitting vaping

Findings from January 2025 Cochrane review

There is limited guidance on the best ways to stop using nicotine containing vapes (otherwise known as e-cigarettes) and ensure long-term abstinence, whilst minimising the risk of tobacco smoking and other unintended consequences.

This briefing document brings you the most up-to-date information from our Cochrane review on the potential benefits and harms of interventions to help people who vape to achieve long-term vaping abstinence. This review is funded by Cancer Research UK

Key findings

- Text message-based interventions may help young people to stop vaping when compared to no or minimal support; however, more evidence is needed.
- Varenicline may help people to stop vaping when compared to no or minimal support; however, more evidence is needed.
- We don't know whether other interventions can help people to stop vaping for six months or more.
- We need more information on potential harms of interventions and whether they cause people to return to, or take up, smoking tobacco

About Cochrane reviews

Cochrane reviews bring together the best available evidence from research and systematically review this information to determine the benefits and risks of treatments. Cochrane is a non-profit organisation. Cochrane Reviews are internationally recognized as the highest standard in evidence-based reviews.

How many studies did we find?

This Cochrane systematic review included 9 studies, representing 5209 participants. In order to keep the information as up-to-date as possible we will search monthly for new evidence - a living systematic review. The January 2025 review includes search findings up to 24th April 2024.

Why this topic is important?

Nicotine vapes expose users to less of the substances that cause disease that are present in tobacco cigarettes. However, vaping is likely to cause more harm than not vaping. Some people vape nicotine to help them quit smoking; however, some people who vape nicotine have never smoked. People may want to stop using vapes containing nicotine, but find it difficult due to nicotine's addictive properties.

Unanswered questions & future research

More randomized controlled trials are needed with long-term follow up. As data continue to emerge we will update our analyses to ensure decision-makers have the best available evidence to hand when considering how to advise people to stop using vapes

Which interventions could help people stop vaping?

Medicines including nicotine replacement therapy (gums, patches, etc.), varenicline, bupropion, and cytisine are already used to help people stop smoking and could be used for stopping vaping. Behavioural interventions could include counselling, text messaging, online support, print-based information and programmes that change vaping behaviour or vape characteristics.

SEARCH UPDATE...we will update this box monthly with information on eligible studies we have found in our searches each month

For all references and the most up to date 2025 Cochrane Review follow this [link](#).

For further information please visit our [webpage](#).

Disclaimer: the views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the funder

The process

Databases were searched for randomized trials recruiting people of any age using nicotine containing vapes, regardless of tobacco smoking status. Studies had to test an intervention designed to support people to quit vaping, and plan to measure at least one of our outcomes. The main outcomes were:

- How many people stopped using nicotine vapes at least 6 months after study start (also measured between 3 & 6 months);
- Change in tobacco smoking at least 6 months after study start (also measured between 3 & 6 months);
- How many people experienced reporting serious adverse events (SAEs) and adverse events (AEs) of treatment, at least one week after treatment started;
- Change in biological markers (e.g. blood pressure; biomarkers of harm)

Summary of findings tables were made for main comparisons and outcomes. We identified nine RCTs.

Funding

Of the nine studies that reported funding information four were funded by the manufacturer or provider of the intervention (Caponnetto 2023; Rigotti 2024; Graham 2021; NCT04919590).

Summary of findings tables

Summary of findings tables were made for main comparisons and outcomes, see following pages.

1. Combination NRT compared to control for nicotine vaping cessation
2. Cytisine compared to placebo for nicotine vaping cessation
3. Varenicline compared to control for nicotine vaping cessation
4. Nicotine/vaping reduction compared to minimal support for nicotine vaping cessation
5. Text message-based interventions compared to no/minimal support for nicotine vaping cessation in young people (13-24 years)

GRADE ratings were used to evaluate certainty in the evidence and can be interpreted as follows.

Grade Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect


GRADE (Grading of Recommendations, Assessment, Development and Evaluations)

[See our full review](#)

[Visit our webpage](#)

[Listen to our podcast](#)

[Cochrane IQV review](#)



1. Summary of Findings: Combination NRT compared to control for nicotine vaping cessation

Combination NRT compared to control for nicotine vaping cessation

Patient or population: people who use nicotine vapes
 Setting: USA
 Intervention: combination NRT
 Comparison: control

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)
	Risk with control	Risk with combination NRT			
Vaping cessation at 6 months or longer follow up: 6 months	Study population		RR 2.57 (0.29 to 22.93)	16 (1 RCTs)	⊕⊖⊖⊖ Very low ^{a, b}
	11 per 100	29 per 100 (3 to 100)			
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
Number of participants reporting serious adverse events at follow up: 3 months Assessed via self-report and medical records	Study population		Not pooled**	508 (1 RCT)	⊕⊕⊖⊖ Low ^c
	Not pooled**	Not pooled**			

*The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

** It was not possible to calculate relative or absolute effects as no events were reported across study arms.

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to risk of bias: only study contributing to comparison and outcome was judged to be at high risk of bias

^b Downgraded two levels due to imprecision: extremely low number of events across arms (n=3) and 95% CI incorporate the potential for benefit, harm and no effect of the intervention.

^c Downgraded two levels due to imprecision: no events recorded across study arms

2. Summary of Findings: Cytisine compared to placebo for nicotine vaping cessation

Cytisine compared to placebo for nicotine vaping cessation					
Patient or population: people who use nicotine vapes					
Setting: USA					
Intervention: cytisine					
Comparison: placebo					
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)
	Risk with placebo	Risk with cytisine			
Vaping cessation at 6 months or longer – not reported	Study population			No studies reported this outcome	
	-				
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
	-				
Number of participants reporting serious adverse events at follow up: 4 months Assessed via self-report and medical records	Study population		Not pooled**	159 (1 RCT)	⊕⊕⊖⊖ Low ^a
	Not pooled**	Not pooled**			

*The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

** It was not possible to calculate relative or absolute effects as no events were reported across study arms.

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to imprecision. No events were reported across study arms.

3. Summary of Findings: Varenicline compared to control for nicotine vaping cessation

Varenicline compared to control for nicotine vaping cessation

• Patient or population: people who use nicotine vapes
 Setting: Italy and USA
 Intervention: varenicline
 Comparison: control

Outcomes	Anticipated absolute effects [†] (95% CI)		Relative effect (95% CI)	N ^o of participants (studies)	Certainty of the evidence (GRADE)
	Risk with control	Risk with varenicline			
Vaping cessation at 6 months or longer follow up: 6 months	Study population 24 per 100	49 per 100 (26 to 89)	RR 2.00 (1.09 to 3.68)	140 (1 RCTs)	⊕⊕⊖⊖ LOW ^a
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
Number of participants reporting serious adverse events at follow up: range 3 months to 6 months Assessed via self-report and medical records	Study population Absolute effects: n/a (the one study contributing to this comparison that reported events did not report events in the control arm, so an accurate absolute risk for the treatment group could not be calculated) RR 2.60 (95% CI 0.11 to 62.16)			130 (3 RCTs)	⊕⊕⊖⊖ LOW ^b

[†]The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to imprecision: small number of events (n=36) reported across study

^b Downgraded two levels due to imprecision: very few events and 95% CI incorporate the potential for benefit, harm and no effect of the intervention

4. Summary of Findings: Nicotine/vaping reduction compared to minimal support for nicotine vaping cessation

Nicotine/vaping reduction compared to minimal support for nicotine vaping cessation

- Patient or population: people who use nicotine vapes
Setting: USA
Intervention: nicotine/vaping reduction
Comparison: minimal support

Outcomes	Anticipated absolute effects [†] (95% CI)		Relative effect (95% CI)	N ^o of participants (studies)	Certainty of the evidence (GRADE)
	Risk with minimal support	Risk with nicotine/vaping reduction			
Vaping cessation at 6 months or longer follow up: 6 months	Study population 11 per 100	38 per 100 (5 to 100)	RR 3.38 (0.43 to 26.30)	17 (1 RCT)	⊕⊖⊖⊖ Very low ^{a,b}
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
Number of participants reporting serious adverse events at follow up: range 3 months to 6 months Assessed via self-report and medical records	Study population			No studies reported this outcome	

[†]The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to risk of bias: the only study contributing to the comparison and outcome was judged to be at high risk of bias

^b Downgraded two levels due to imprecision: extremely low number of events across study arms and 95% CI encompassing the potential for benefit, harm and no effect of the intervention

5. Summary of Findings: Text message-based interventions compared to no/minimal support for nicotine vaping cessation in young people (13-24 years)

Varenicline compared to control for nicotine vaping cessation

- Patient or population: people who use nicotine vapes
Setting: USA
Intervention: text message-based interventions
Comparison: control

Outcomes	Anticipated absolute effects [†] (95% CI)		Relative effect (95% CI)	N ^o of participants (studies)	Certainty of the evidence (GRADE)
	Risk with no/minimal support	Risk with text message-based interventions			
Vaping cessation at 6 months or longer follow up: 6 months	Study population 22 per 100	29 per 100 (26 to 32)	RR 1.32 (1.19 to 1.47)	4091 (2 RCTs)	⊕⊕⊖⊖ LOW ^{a,b}
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
Number of participants reporting serious adverse events at follow up: range 3 months to 6 months Assessed via self-report and medical records	Study population Not pooled ^{**}	Not pooled ^{**}	Not pooled ^{**}	508 (1 RCT)	⊕⊕⊖⊖ LOW ^c

[†]The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

^{**} We did not calculate relative or absolute effects as there were no events across study arms

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Not downgraded due to risk of bias; one of the two studies was unpublished at the time of writing and was judged to be at unclear risk of bias due to insufficient data with which to judge some domains. The other study was judged at low risk across all domains assessed, and there was no evidence of a difference between study results.

^b Downgraded two levels due to indirectness: the two contributing studies tested the same intervention in a relatively homogenous population. Unclear if the effects can be generalised to other text message-based interventions and other populations

^c Downgraded two levels due to imprecision. No events were recorded across study arms.